Re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries

Open letters to Indian Prime Minister and Health Minister to support India’s refusal of any Trade-Related Aspects of Intellectual Property Rights (TRIPS)-Plus Provisions in Free-Trade Agreement negotiations with the European Union.

Open letter to the European Medicines Agency regarding the filing of the drugs delamanid and bedaquiline for market approval.

Determining a fair and affordable price of bedaquiline is essential for timely approval and appropriate domestic and global access to the best possible therapeutic options for people with DR-TB.

3rd Annual South African TB Conference, Durban 2012
Date: 14 June 2012
Time: 14h00 – 15h30
Location: Hall 3B

Open letters to Otsuka, Janssen Pharmaceutical Companies of Johnson & Johnson, Food and Drug Administration and European Medicines Agency.

Open letter regarding Cepheid pricing of the GeneXpert machines and  cartridges for high-burden settings in the public and private sectors.

Open letter to the Medicines Control Council and Ministry of Health on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa.